Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice
Date
2021-04-13Journal
Proceedings of the National Academy of SciencesPublisher
National Academy of SciencesType
Article
Metadata
Show full item recordAbstract
Depression is a widespread and devastating mental illness and the search for rapid-acting antidepressants remains critical. There is now exciting evidence that the psychedelic compound psilocybin produces not only powerful alterations of consciousness, but also rapid and persistent antidepressant effects. How psilocybin exerts its therapeutic actions is not known, but it is widely presumed that these actions require altered consciousness, which is known to be dependent on serotonin 2A receptor (5-HT2AR) activation. This hypothesis has never been tested, however. We therefore asked whether psilocybin would exert antidepressant-like responses in mice and, if so, whether these responses required 5-HT2AR activation. Using chronically stressed male mice, we observed that a single injection of psilocybin reversed anhedonic responses assessed with the sucrose preference and female urine preference tests. The antianhedonic response to psilocybin was accompanied by a strengthening of excitatory synapses in the hippocampus-a characteristic of traditional and fast-acting antidepressants. Neither behavioral nor electrophysiological responses to psilocybin were prevented by pretreatment with the 5-HT2A/2C antagonist ketanserin, despite positive evidence of ketanserin's efficacy. We conclude that psilocybin's mechanism of antidepressant action can be studied in animal models and suggest that altered perception may not be required for its antidepressant effects. We further suggest that a 5-HT2AR-independent restoration of synaptic strength in cortico-mesolimbic reward circuits may contribute to its antidepressant action. The possibility of combining psychedelic compounds and a 5-HT2AR antagonist offers a potential means to increase their acceptance and clinical utility and should be studied in human depression.Sponsors
Office of Extramural Research, National Institutes of HealthIdentifier to cite or link to this item
http://hdl.handle.net/10713/15426ae974a485f413a2113503eed53cd6c53
10.1073/pnas.2022489118
Scopus Count
Collections
Related articles
- Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
- Authors: Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbæk DS, Kristiansen S, Johansen SS, Lehel S, Linnet K, Svarer C, Erritzoe D, Ozenne B, Knudsen GM
- Issue date: 2019 Jun
- A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT(2A) Receptor Density in the Pig Brain.
- Authors: Raval NR, Johansen A, Donovan LL, Ros NF, Ozenne B, Hansen HD, Knudsen GM
- Issue date: 2021 Jan 15
- Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice.
- Authors: Odland AU, Kristensen JL, Andreasen JT
- Issue date: 2021 Mar 5
- Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.
- Authors: Stenbæk DS, Madsen MK, Ozenne B, Kristiansen S, Burmester D, Erritzoe D, Knudsen GM, Fisher PM
- Issue date: 2021 Apr
- Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans.
- Authors: Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB, Vollenweider FX
- Issue date: 2007 Dec